Biotech Values

[DewDiligence]

If BMY overpaid for INHX, does it follow that BMY underpaid for ZGEN??

What’s clear is that BMY now treats Lambda as but an afterthought when discussing its pipeline at investor conferences—if it is even mentioned at all. As noted in my previous post, that’s sufficient evidence for me that ZGEN shareholders were not robbed.